Tan C, Wong B, Goh D Y, Van Bever H P
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Singapore Med J. 2009 Jan;50(1):54-61.
Asthma is the most common chronic disease in children in Singapore. More than 20 percent of children will have been diagnosed with asthma by the age of 15 years. Most children are seen in the primary care setting, thus it is of value to study the management practices, especially of general practitioners, with comparison to gold standards. The aims of the study were to investigate: (a) Methods of monitoring asthma control; (b) Practices in managing acute exacerbations; and (c) Choice of therapy in maintenance treatment.
2,100 questionnaires consisting of 35 questions were sent by post to general practitioners and various paediatric doctors throughout Singapore. 173 valid responses were received and results were compared to the 2006 Global Initiative for Asthma guidelines.
76.3 percent of respondents were general practitioners. 89.1 percent did not use symptom score cards / diaries. 37.6 percent did not use peak-flow meters / spirometers. 83.8 percent used a short-acting beta-agonist in acute exacerbations, but only 41.0 percent used oral corticosteroids in outpatients. A significant number used long-acting beta-agonists (LABA) in combination with inhaled steroids (29.5-41.6 percent) or as monotherapy (5.8-8.7 percent) for maintenance treatment. 91.3 percent never used immunotherapy in practice.
Greater usage of diaries / score cards can be encouraged along with objective peak flow / spirometry measurements. Management of acute exacerbations is appropriate but corticosteroids are under-prescribed by most doctors. LABA continues to be prescribed for maintenance despite a lack of established safety profile for infants, along with recommendations that they only be used selectively in patients poorly-controlled by medium-dosage inhaled corticosteroids.
哮喘是新加坡儿童中最常见的慢性疾病。超过20%的儿童在15岁时会被诊断出患有哮喘。大多数儿童在初级保健机构就诊,因此研究管理方法,尤其是全科医生的管理方法,并与金标准进行比较具有重要意义。本研究的目的是调查:(a) 监测哮喘控制的方法;(b) 管理急性加重期的做法;以及(c) 维持治疗中的治疗选择。
通过邮寄向新加坡各地的全科医生和各类儿科医生发送了2100份包含35个问题的问卷。共收到173份有效回复,并将结果与2006年全球哮喘防治创议指南进行了比较。
76.3%的受访者为全科医生。89.1%的人未使用症状评分卡/日记。37.6%的人未使用峰值流量计/肺活量计。83.8%的人在急性加重期使用短效β受体激动剂,但只有41.0%的人在门诊使用口服糖皮质激素。相当一部分人在维持治疗中使用长效β受体激动剂(LABA)与吸入性糖皮质激素联合使用(29.5 - 41.6%)或作为单一疗法(5.8 - 8.7%)。91.3%的人在实际中从未使用过免疫疗法。
可以鼓励更多地使用日记/评分卡以及进行客观的峰值流量/肺活量测定。急性加重期的管理是恰当的,但大多数医生对糖皮质激素的处方不足。尽管缺乏针对婴儿的既定安全性资料,且建议仅在中剂量吸入性糖皮质激素治疗效果不佳的患者中选择性使用,但LABA仍继续被用于维持治疗。